Phase 2 Brain Cancer Trial, Recruiting NCT07248228 Sponsor: Case Comprehensive Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT07248228
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a solid tumour (confirmed by tissue sample, cell sample, or imaging) that has spread to the brain
  • People who are older than 18 years of age
  • People who are well enough to carry out most daily activities, as measured by a standard medical scale called the Karnofsky Performance Status, with a score of 70 or above (confirm with trial site)
  • People who have an estimated life expectancy of at least 3 months
  • People whose treating doctor considers them a suitable candidate for whole brain radiation therapy (a type of radiation treatment targeting the entire brain)
  • People who speak English as their primary language and are able to understand and sign a written consent form in English
  • People who have at least 10 brain metastases (areas where cancer has spread in the brain), or who are otherwise considered suitable for whole brain radiation therapy by their treating doctor

Who may not be able to join:

  • People who have previously received whole brain radiation therapy
  • People who have Multiple Sclerosis, Alzheimer's disease, dementia, or a mental disability
  • People who are pregnant or breastfeeding
  • People who are unable to have an MRI scan
  • People whose cancer has spread into certain specific brain structures involved in memory and cognition, including the hippocampus, amygdala, fornix, corpus callosum, or pituitary gland (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Haley Perlow, MD, Case Comprehensive Cancer Center, University Hospitals

Phone: (216) 286-3906

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Time to neurocognitive failure (NCF); Hopkins Verbal Learning Test-Revised (HVLT-R); Hopkins Verbal Learning Test-Revised (HVLT-R); Hopkins Verbal Learning Test-Revised (HVLT-R); Hopkins Verbal Learning Test-Revised (HVLT-R); Hopkins Verbal Learning Test-Revised (HVLT-R); Controlled Oral Word Association Test (COWAT); Controlled Oral Word Association Test (COWAT); Controlled Oral Word Association Test (COWAT); Controlled Oral Word Association Test (COWAT); Controlled Oral Word Association Test (COWAT); Brief Visuospatial Memory Test-Revised (BVMT-R); Brief Visuospatial Memory Test-Revised (BVM...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov